CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

por Naing, Aung, Thistlethwaite, Fiona, De Vries, Elisabeth G.E., Eskens, Ferry A.L.M., Uboha, Nataliya, Ott, Patrick A., LoRusso, Patricia, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A., Randhawa, Manreet, Durm, Greg, Gil-Martin, Marta, Stroh, Mark, Hannah, Alison L., Arkenau, Hendrik-Tobias, Spira, Alexander
Publicado 2021